Nutex Health Inc. (NUTX)
Bet on These 4 Stocks With Strong Net Profit Margins to Boost Returns
Let's take a look at four stocks, NUTX, RCMT, TILE and QUAD, with impressive net profit margins for a robust portfolio.
Nutex Health: A High-Risk, High-Reward Play For Speculative Investors
Nutex Health has surged 134% since April, driven by its out-of-network micro-hospital model and expanding margins. It has staged a turnaround in 2026, driven by strong EPS growth after years of struggle. The company leverages the No Surprises Act's arbitration process to sustain margins against insurer underpayment, making dispute resolution central to its current business.
What Makes Nutex Health (NUTX) a Good Fit for 'Trend Investing'
Nutex Health (NUTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Nutex Health Inc. (NUTX) is a Great Momentum Stock: Should You Buy?
Does Nutex Health Inc. (NUTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why 'Trend' Investors Would Love Betting on Nutex Health (NUTX)
Nutex Health (NUTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Surging Earnings Estimates Signal Upside for Nutex Health (NUTX) Stock
Nutex Health Inc. (NUTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods.
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript
Nutex Health Q2 Earnings Call Highlights
Nutex Health NASDAQ: NUTX reported higher second-quarter profitability and adjusted EBITDA despite lower revenue, as the company benefited from reduced arbitration-related costs, lower stock-based compensation and continued patient-volume growth.
Nutex Health Has A Healthy Pulse And Shows Strong Signs Of Life For Further Gains
Nutex Health is rated Buy, with a DCF-based price target of $199.31, offering 19.8% upside from $166.40. NUTX's revenue surged from $247.6M in FY2023 to $880.0M TTM ended March 31, 2026, driven by effective use of the No Surprises Act's IDR process. Liquidity and leverage metrics have improved, with debt-to-equity falling below 1.0 and the current ratio at 3.1 in the TTM period.
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
